Form 4: Celularity Director Diane Parks Granted 61,539 RSUs

Celularity Inc. Director Diane L. Parks received a grant of 61,539 restricted stock units, increasing her beneficial ownership to 365,021 shares.

Summary

• Diane L. Parks, a Director of Celularity Inc. (CELU), acquired 61,539 shares of Class A Common Stock.
• The transaction occurred on November 19, 2025, with a price of $0.00 per share, indicating a grant.
• These shares represent Restricted Stock Units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU entitles the holder to receive one share of the Issuer's Class A common stock.
• The RSUs vest and become exercisable on the date of grant.
• Following this transaction, Diane L. Parks beneficially owns a total of 365,021 shares.

Sentiment

Score: 6

Explanation: The filing reports a routine insider equity grant, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management and director interests with those of shareholders, as their compensation is tied to the company's performance.
• The transaction is part of the Celularity Inc. 2021 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions, common in the biotechnology and healthcare sectors where equity compensation is a significant component of executive and director remuneration. It reflects a routine grant under an established equity plan, aligning with common industry practices for incentivizing leadership.

Comparison to Industry Standards

• The grant of RSUs to a director is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain talent and align interests with shareholders.
• The use of an 'Equity Incentive Plan' (Celularity Inc. 2021 Equity Incentive Plan) is standard for managing and distributing equity compensation, comparable to plans at companies like Moderna (MRNA) or BioNTech (BNTX) which also utilize equity grants for their leadership.

Related Party Transactions

• The acquisition of 61,539 shares by Director Diane L. Parks is a related party transaction, as it involves an insider receiving equity compensation from the company.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be seen as a positive for shareholders as it aligns the director's financial interests with the company's long-term performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention efforts.

Key Dates

Keywords

Celularity Inc., CELU, Diane L. Parks, Restricted Stock Units, RSUs, Equity Incentive Plan, Insider Transaction, Director Compensation, SEC Form 4